Aerie Pharmaceuticals
| Company type | Subsidiary |
|---|---|
| Nasdaq: AERI | |
| Industry |
|
| Founded | 2005 |
| Founders |
|
| Headquarters | Durham, North Carolina, U.S. |
| Parent | Alcon |
| Website | aeriepharma |
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.[1][2][3]
In August 2022, Swiss eye-care firm Alcon agreed to buy Aerie Pharmaceuticals for US$770 million.[4] The acquisition completed in November 2022.[5]
References
[edit]- ^ Witkowski, Wallace (16 September 2015). "Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results". Fox Business.[permanent dead link]
- ^ Beckerman, Josh (16 September 2015). "Aerie Pharmaceuticals Shares Rise on Trial Results". Wall Street Journal.
- ^ "Aerie Pharma shares battered as eye drug fails study". Reuters. 23 April 2015. Retrieved 7 January 2016.
- ^ "Alcon buys the American Aerie Pharmaceuticals for 770 million". Swissinfo (in French). 23 August 2022.
- ^ Ezzone, Zac (23 November 2022). "Durham loses public company HQ with Alcon-Aerie deal complete". American City Business Journals. Archived from the original on 1 December 2022.
